Biodexa Pharmaceuticals' MAGIC-1 study of MTX110 for recurrent glioblastoma shows improved survival rates.

Biodexa Pharmaceuticals announced positive results from its MAGIC-1 study of MTX110, a treatment for recurrent glioblastoma (rGBM), a severe brain cancer. MTX110 combines the drug panobinostat with a convection-enhanced delivery system that directly targets tumors, effectively bypassing the blood-brain barrier. The study shows improved progression-free and overall survival rates, suggesting a potential shift in treatment standards for rGBM and aggressive brain cancers like diffuse midline glioma.

October 17, 2024
5 Articles

Further Reading